Abstract
Abstract. The number of strokes and deaths from stroke is increasing every year in the world, with ischemic stroke (IS) accounting for about 80% of cases. The purpose of this review is to analyze the results of studies evaluating the significance of measuring various biomarkers in predicting the risk of developing IS. To date, studies are actively exploring the prospects of a number of inflammatory (C-reactive protein, fibrinogen, pro-inflammatory cytokines, etc.), hemodynamic, cardiac, and metabolic biomarkers that can be used to improve the accuracy of IS risk stratification. Currently, it is difficult to isolate the screening biomarker that is the most diagnostically significant for assessing the risk of stroke. Thus, according to a number of studies and meta-analyses, highly sensitive C-reactive protein is a diagnostically significant biomarker of IS. The role of highly sensitive troponin I and natriuretic peptide in diagnosing the risk of IS requires further study. Evaluation of triglyceride-glucose index, apolipoprotein B, apolipoprotein A1, asymmetric dimethylarginine, uric acid seems promising. However, their possible role in the reclassification of asymptomatic patients in addition to the existing scales based on traditional risk factors remains to be elucidated
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
